Lumos Pharma, Inc. (LUMO) |
| 4.34 0 (0%) 12-11 16:00 |
| Open: | 4.33 |
| High: | 4.34 |
| Low: | 4.33 |
| Volume: | 390,873 |
| Market Cap: | 38(M) |
| PE Ratio: | -1.01 |
| Exchange: | NASDAQ Global Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 13.20 |
| Resistance 1: | 11.30 |
| Pivot price: | 10.08 |
| Support 1: | 9.35 |
| Support 2: | 8.15 |
| 52w High: | 4.5756 |
| 52w Low: | 1.3701 |
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
Financials
| EPS | -1.750 |
| Book Value | -1.090 |
| PEG Ratio | 17.14 |
| Gross Profit | 5.563 |
| Profit Margin (%) | -14.34 |
| Operating Margin (%) | -0.69 |
| Return on Assets (ttm) | -0.8 |
| Return on Equity (ttm) | 0.0 |
Company news
Thu, 24 Apr 2025
Lumos Pharma Stock Price, News & Analysis - Stock Titan
Thu, 24 Oct 2024
DPV set to acquire Lumos Pharma for $38m - Pharmaceutical Technology
Wed, 08 Nov 2023
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday - InvestorPlace
Sun, 04 Dec 2022
Bradley J Powers Net Worth (2026) - GuruFocus
Sat, 03 Dec 2022
John C. Mckew Net Worth (2026) - GuruFocus
Tue, 01 Oct 2019
NewLink’s two-decade run ends in reverse merger, layoffs - BioPharma Dive
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
